Based on the measurements of operating efficiency obtained from Bio Techne's historical financial statements, Bio Techne Corp may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. As of now, Bio Techne's Total Current Liabilities is increasing as compared to previous years. The Bio Techne's current Total Stockholder Equity is estimated to increase to about 2 B, while Cash is projected to decrease to under 91.9 M. Key indicators impacting Bio Techne's financial strength include:
The essential information of the day-to-day investment outlook for Bio Techne includes many different criteria found on its balance sheet. An individual investor should monitor Bio Techne's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Bio Techne.
Bio Techne competes with United Therapeutics, Incyte, Vaxcyte, Legend Biotech, and Ascendis Pharma. Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. Bio-Techne operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3000 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Bio Techne's current stock value. Our valuation model uses many indicators to compare Bio Techne value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bio Techne competition to find correlations between indicators driving Bio Techne's intrinsic value. More Info.
Bio Techne Corp is rated below average in return on equity category among its peers. It is rated third in return on asset category among its peers reporting about 1.71 of Return On Asset per Return On Equity. As of now, Bio Techne's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bio Techne's earnings, one of the primary drivers of an investment's value.
Bio Techne's Earnings Breakdown by Geography
Bio Techne Corp Systematic Risk
Bio Techne's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bio Techne volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Bio Techne Corp correlated with the market. If Beta is less than 0 Bio Techne generally moves in the opposite direction as compared to the market. If Bio Techne Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bio Techne Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bio Techne is generally in the same direction as the market. If Beta > 1 Bio Techne moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Bio Techne Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bio Techne's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bio Techne growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Bio Techne help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bio Techne Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bio Techne Corp based on widely used predictive technical indicators. In general, we focus on analyzing Bio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bio Techne's daily price indicators and compare them against related drivers.
When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.